Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

Insights into Interactions between Interleukin-6 and Dendritic Polyglycerols (CROSBI ID 292003)

Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija

Sanader Maršić, Željka ; Maysinger, Dušica ; Bonačić- Kouteckỳ, Vlasta Insights into Interactions between Interleukin-6 and Dendritic Polyglycerols // International journal of molecular sciences, 22 (2021), 5; 2415, 15. doi: 10.3390/ijms22052415

Podaci o odgovornosti

Sanader Maršić, Željka ; Maysinger, Dušica ; Bonačić- Kouteckỳ, Vlasta

engleski

Insights into Interactions between Interleukin-6 and Dendritic Polyglycerols

Interleukin-6 (IL-6) is involved in physiological and pathological processes. Different pharmacological agents have been developed to block IL-6 deleterious effects and to recover homeostatic IL-6 signaling. One of the proposed nanostructures in pre-clinical investigations which reduced IL-6 concentrations is polyglycerol dendrimer, a nano-structure with multiple sulfate groups. The aim of the present study was to uncover the type of binding between critical positions in the human IL-6 structure available for binding dPGS and compare it with heparin sulfate binding. We studied these interactions by performing docking simulations of dPGS and heparins with human IL-6 using AutoDock Vina. These molecular docking analyses indicate that the two ligands have comparable affinities for the positively charged positions on the surface of IL-6. All-atom molecular dynamics simulations (MD) employing Gromacs were used to explore the binding sites and binding strengths. Results suggest two major binding sites and show that the strengths of binding are similar for heparin and dPGS (−5.5–6.4 kcal/ mol). dPGS or its analogs could be used in the therapeutic intervention in sepsis and inflammatory disorders to reduce unbound IL-6 in the plasma or tissues and its binding to the receptors. We propose that analogs of dPGS could specifically block IL-6 binding in the desired signaling mode and would be valuable new probes to establish optimized therapeutic intervention in inflammation.

interleukin-6 ; inflammation ; heparin ; dendritic polyglycerols ; molecular docking ; anti-inflammatory nanostructures ; protein-dendrimer interaction

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

22 (5)

2021.

2415

15

objavljeno

1422-0067

10.3390/ijms22052415

Povezanost rada

Fizika

Poveznice
Indeksiranost